vs
Side-by-side financial comparison of Acadia Healthcare Company, Inc. (ACHC) and Magnera Corp (MAGN). Click either name above to swap in a different company.
Acadia Healthcare Company, Inc. is the larger business by last-quarter revenue ($829.0M vs $792.0M, roughly 1.0× Magnera Corp). Acadia Healthcare Company, Inc. runs the higher net margin — 0.5% vs -4.3%, a 4.8% gap on every dollar of revenue. On growth, Magnera Corp posted the faster year-over-year revenue change (12.8% vs 7.5%). Over the past eight quarters, Magnera Corp's revenue compounded faster (54.9% CAGR vs 2.0%).
Acadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico.
ACHC vs MAGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $829.0M | $792.0M |
| Net Profit | $4.5M | $-34.0M |
| Gross Margin | — | 12.2% |
| Operating Margin | — | 1.8% |
| Net Margin | 0.5% | -4.3% |
| Revenue YoY | 7.5% | 12.8% |
| Net Profit YoY | -50.8% | 43.3% |
| EPS (diluted) | $0.05 | $-0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $829.0M | — | ||
| Q4 25 | $821.5M | $792.0M | ||
| Q3 25 | $851.6M | — | ||
| Q2 25 | $869.2M | $839.0M | ||
| Q1 25 | $770.5M | $824.0M | ||
| Q4 24 | $774.2M | $702.0M | ||
| Q3 24 | $815.6M | $332.1M | ||
| Q2 24 | $796.0M | $556.0M |
| Q1 26 | $4.5M | — | ||
| Q4 25 | $-1.2B | $-34.0M | ||
| Q3 25 | $36.2M | — | ||
| Q2 25 | $30.1M | $-18.0M | ||
| Q1 25 | $8.4M | $-41.0M | ||
| Q4 24 | $32.6M | $-60.0M | ||
| Q3 24 | $68.1M | $-15.2M | ||
| Q2 24 | $78.5M | $19.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 10.7% | ||
| Q1 25 | — | 10.7% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | -142.4% | 1.8% | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 5.8% | 1.5% | ||
| Q1 25 | 1.7% | 0.5% | ||
| Q4 24 | 4.9% | -3.1% | ||
| Q3 24 | 12.1% | 0.9% | ||
| Q2 24 | 13.4% | 3.1% |
| Q1 26 | 0.5% | — | ||
| Q4 25 | -143.3% | -4.3% | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 3.5% | -2.1% | ||
| Q1 25 | 1.1% | -5.0% | ||
| Q4 24 | 4.2% | -8.5% | ||
| Q3 24 | 8.4% | -4.6% | ||
| Q2 24 | 9.9% | 3.4% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-12.98 | $-0.95 | ||
| Q3 25 | $0.40 | — | ||
| Q2 25 | $0.33 | $-0.51 | ||
| Q1 25 | $0.09 | $-1.15 | ||
| Q4 24 | $0.36 | $-1.69 | ||
| Q3 24 | $0.74 | $-0.33 | ||
| Q2 24 | $0.85 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $158.5M | $264.0M |
| Total DebtLower is stronger | $2.5B | $1.9B |
| Stockholders' EquityBook value | $2.0B | $1.0B |
| Total Assets | $5.5B | $3.9B |
| Debt / EquityLower = less leverage | 1.29× | 1.86× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $158.5M | — | ||
| Q4 25 | $133.2M | $264.0M | ||
| Q3 25 | $118.7M | — | ||
| Q2 25 | $131.4M | $276.0M | ||
| Q1 25 | $91.2M | $282.0M | ||
| Q4 24 | $76.3M | $215.0M | ||
| Q3 24 | $82.1M | $230.0M | ||
| Q2 24 | $77.2M | $33.9M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $1.9B | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | $2.0B | ||
| Q1 25 | $2.2B | $2.0B | ||
| Q4 24 | $2.0B | $2.0B | ||
| Q3 24 | $1.9B | $2.0B | ||
| Q2 24 | $1.8B | $877.4M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $1.0B | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $3.1B | $1.1B | ||
| Q1 25 | $3.0B | $1.1B | ||
| Q4 24 | $3.1B | $1.1B | ||
| Q3 24 | $3.0B | $2.1B | ||
| Q2 24 | $3.0B | $2.4B |
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.5B | $3.9B | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.3B | $4.1B | ||
| Q1 25 | $6.1B | $4.1B | ||
| Q4 24 | $6.0B | $4.0B | ||
| Q3 24 | $5.9B | $2.8B | ||
| Q2 24 | $5.7B | $1.5B |
| Q1 26 | 1.29× | — | ||
| Q4 25 | 1.28× | 1.86× | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.74× | 1.77× | ||
| Q1 25 | 0.72× | 1.83× | ||
| Q4 24 | 0.64× | 1.80× | ||
| Q3 24 | 0.62× | 0.91× | ||
| Q2 24 | 0.62× | 0.37× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $61.5M | $2.0M |
| Free Cash FlowOCF − Capex | — | $-13.0M |
| FCF MarginFCF / Revenue | — | -1.6% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 13.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $61.5M | — | ||
| Q4 25 | $-86.3M | $2.0M | ||
| Q3 25 | $73.2M | — | ||
| Q2 25 | $133.5M | $0 | ||
| Q1 25 | $11.5M | $65.0M | ||
| Q4 24 | $116.7M | $-58.0M | ||
| Q3 24 | $163.1M | $12.2M | ||
| Q2 24 | $171.1M | $38.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-179.5M | $-13.0M | ||
| Q3 25 | $-63.0M | — | ||
| Q2 25 | $-34.2M | — | ||
| Q1 25 | $-163.2M | $42.0M | ||
| Q4 24 | $-86.8M | $-74.0M | ||
| Q3 24 | $-27.1M | $3.6M | ||
| Q2 24 | $16.9M | $23.0M |
| Q1 26 | — | — | ||
| Q4 25 | -21.8% | -1.6% | ||
| Q3 25 | -7.4% | — | ||
| Q2 25 | -3.9% | — | ||
| Q1 25 | -21.2% | 5.1% | ||
| Q4 24 | -11.2% | -10.5% | ||
| Q3 24 | -3.3% | 1.1% | ||
| Q2 24 | 2.1% | 4.1% |
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | 1.9% | ||
| Q3 25 | 16.0% | — | ||
| Q2 25 | 19.3% | 1.5% | ||
| Q1 25 | 22.7% | 2.8% | ||
| Q4 24 | 26.3% | 2.3% | ||
| Q3 24 | 23.3% | 2.6% | ||
| Q2 24 | 19.4% | 2.7% |
| Q1 26 | 13.78× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 4.43× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 2.39× | — | ||
| Q2 24 | 2.18× | 2.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACHC
| Acute Inpatient Psychiatric Facilities | $471.0M | 57% |
| Other | $140.0M | 17% |
| Specialty Treatment Facilities | $128.0M | 15% |
| Residential Treatment Facilities | $90.0M | 11% |
MAGN
| Other | $451.0M | 57% |
| United States And Canada | $341.0M | 43% |
